<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02321228</url>
  </required_header>
  <id_info>
    <org_study_id>NL50048.091.14</org_study_id>
    <nct_id>NCT02321228</nct_id>
  </id_info>
  <brief_title>Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers</brief_title>
  <acronym>TUBA</acronym>
  <official_title>Early Salpingectomy (Tubectomy) With Delayed Oophorectomy to Improve Quality of Life as Alternative for Risk Reducing Salpingo-oophorectomy in BRCA1/2 Gene Mutation Carriers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Nijmegen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Nijmegen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether an innovative preventive strategy,
      consisting of early salpingectomy upon completion of childbearing with delayed oophorectomy
      beyond current guideline age, improves menopause-related quality of life without
      significantly increasing ovarian cancer incidence in comparison to current standard
      salpingo-oophorectomy in female BRCA1/2 mutation carriers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible women will choose for the innovative or standard risk-reducing option themselves.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">January 2035</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Menopause-related quality of life</measure>
    <time_frame>Up to 5 years after last surgery</time_frame>
    <description>Measured by the Greene Climacteric Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>General quality of life</measure>
    <time_frame>Up to 15 years after last surgery</time_frame>
    <description>measured by several questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life related items</measure>
    <time_frame>Up to 15 years after last surgery</time_frame>
    <description>i.e. sexual functioning, cancer worry, satisfaction with decision</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgery-related complications</measure>
    <time_frame>6 weeks after each surgery</time_frame>
    <description>Surgery-related complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histopathologic findings of removed fallopian tubes and ovaries</measure>
    <time_frame>6 weeks after each surgery</time_frame>
    <description>- Histopathologic findings of removed fallopian tubes and ovaries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk factors</measure>
    <time_frame>Up to 5 years after last surgery</time_frame>
    <description>Limited physical examination: blood pressure, BMI, waist-hip ratio Blood sample Questionnaires on cardiovascular risk factors and diseases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of cardiovascular diseases</measure>
    <time_frame>Up to 15 years after last surgery</time_frame>
    <description>i.e. waist-hip circumference, Fasting blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ovarian cancer</measure>
    <time_frame>Up to 15 years after last surgery</time_frame>
    <description>Incidence of ovarian cancer (cancer of tubes, ovaries and/or peritoneal cancer)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of breast cancer</measure>
    <time_frame>Up to 15 years after last surgery</time_frame>
    <description>Incidence of breast cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness of innovative preventive strategy</measure>
    <time_frame>10 years after last surgery</time_frame>
    <description>Costs per quality adjusted life year (QALY)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">510</enrollment>
  <condition>BRCA1 Gene Mutation</condition>
  <condition>BRCA2 Gene Mutation</condition>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Salpingectomy with delayed oophorectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Female BRCA mutation carriers can opt for early salpingectomy upon completion of childbearing, followed by second stage oophorectomy delayed for five years beyond current guideline ages for risk-reducing salpingo-oophorectomy (i.e. age 40-45 for BRCA1 mutation carriers and 45-50 for BRCA mutation carriers).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risk-reducing salpingo-oophorectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Female BRCA mutation carriers can opt for standard risk-reducing salpingo-oophorectomy at current guideline ages (age 35-40 for BRCA1 mutation carriers and age 40-45 for BRCA2 mutation carriers).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Salpingectomy with delayed oophorectomy</intervention_name>
    <description>Early salpingectomy upon completions of childbearing with postponement of oophorectomy until between 40 and 45 in BRCA1 mutation carriers and between age 45 and 50 in BRCA2 mutation carriers.</description>
    <arm_group_label>Salpingectomy with delayed oophorectomy</arm_group_label>
    <other_name>Tubectomy with delayed oophorectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Risk-reducing salpingo-oophorectomy</intervention_name>
    <description>This is the current guideline procedure, usually performed between age 35 and 40 in BRCA1 mutation carriers and between age 40 and 45 in BRCA2 mutation carriers.</description>
    <arm_group_label>Risk-reducing salpingo-oophorectomy</arm_group_label>
    <other_name>Bilateral prophylactic salpingo-oophorectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal women with a documented BRCA1 and/or BRCA2 germline mutation

          -  Age 25-40 years for BRCA1 mutation carriers, 25-45 years for BRCA2

          -  Childbearing completed

          -  Presence of at least one fallopian tube

          -  Participants may have a personal history of non-ovarian malignancy

        Exclusion Criteria:

          -  Postmenopausal status (natural menopause or due to (cancer) treatment)

          -  Wish for second stage oophorectomy within two years after salpingectomy (if clear at
             enrollment)

          -  Legally incapable

          -  Prior bilateral salpingectomy

          -  A personal history of ovarian, fallopian tube or peritoneal cancer

          -  Evidence of malignant disease at enrollment

          -  Treatment for malignant disease at enrollment

          -  Inability to read or speak Dutch

        BRCA mutation carriers who opt for salpingectomy but who do not want to postpone the
        oophorectomy beyond the guideline age will undergo similar follow-up but do not contribute
        to the 510 inclusions we need
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanne A de Hullu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Nijmegen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosella PM Hermens, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scientific Institute for Quality of Healtcare, UMCNijmegen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicoline Hoogerbrugge, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Nijmegen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Hospital</name>
      <address>
        <city>Eindhoven</city>
        <state>Noord-Brabant</state>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth-TweeSteden Hospital</name>
      <address>
        <city>Tilburg</city>
        <state>Noord-Brabant</state>
        <zip>5042 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute / Antoni van Leeuwenhoek Hospital</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <state>Zuid-Holland</state>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU University Medical center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maxima Medical Center</name>
      <address>
        <city>Veldhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 11, 2014</study_first_submitted>
  <study_first_submitted_qc>December 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2014</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Nijmegen</investigator_affiliation>
    <investigator_full_name>Joanne A. de Hullu, MD, PhD</investigator_full_name>
    <investigator_title>MD, PhD, gynecologic oncologist, principal clinician</investigator_title>
  </responsible_party>
  <keyword>Salpingectomy</keyword>
  <keyword>Delayed oophorectomy</keyword>
  <keyword>Salpingo-oophorectomy</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Ovarian cancer</keyword>
  <keyword>BRCA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

